

Investor Presentation – Fourth Quarter 2018

NASDAQ: HRZN

www.horizontechfinance.com

March 2019

©2019 Horizon. Confidential and proprietary.



Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements which are based on current expectations and assumptions about future events. Forward-looking statements describe future financial or business performance, strategies, or expectations, and are generally identified by words or phrases such as "trend," "opportunity," "pipeline," "believe," "comfortable," "expect," "anticipate," "current," "intention," "estimate," "position," "assume," "plan," "potential," "project," "outlook," "continue," "remain," "maintain," "sustain," "seek," "achieve," and similar expressions, or future of conditional verbs such as "will," "would," "could," "should," "may," or similar expressions. You are cautioned that such statements are subject to a multitude of risks and uncertainties. Actual results could differ materially from historical performance. These forward-looking statements are subject to risks that include, but are not limited to, the following:

- —Future operating results, including the performance of our existing loans and warrants;
- —Introduction, withdrawal, success and timing of business initiatives and strategies;
- —Changes in political, economic or industry conditions, the interest rate environment or financial and capital markets, which could result in changes in the value of our assets;
- —Relative and absolute investment performance and operations of our Advisor;
- —Impact of increased competition;
- —Impact of investments we intend to make and future acquisitions and divestitures;
- —Unfavorable resolution of legal proceedings;
- —Business prospects and the prospects of our portfolio companies;
- —Projected performance of other funds managed by our Advisor;
- —Impact, extent, and timing of technological changes and the adequacy of intellectual property protection;
- -Regulatory structure and tax status;
- —Adequacy of our cash resources and working capital;
- —Timing of cash flows, if any, from the operations of our portfolio companies;
- —Impact of interest rate volatility on our results, particularly if we use leverage as part of our investment strategy;
- —Ability of our portfolio companies to achieve their objective;
- —Impact of legislative and regulatory actions and reforms and regulatory, supervisory or enforcement actions of government agencies relating to us or our Advisor;
- —Contractual arrangements and relationships with third parties;
- —Ability to access capital and any future financings by us;
- —Ability of our Advisor to attract and retain highly trained professionals;
- —Impact of changes to tax legislation and, generally, our tax position; and
- —Other risks and uncertainties described in our SEC filings, available on the SEC's website at www.sec.gov.


You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements speak only as of the date they are made, and we undertake no obligation to update such statements.



HorizonTechnologyFinance

A LIFE SCIENCES & TECHNOLOGY VENTURE LENDING PARTNER

Investment Highlights





Company Overview



UNIQUE & DIFFERENTIATED STRATEGY

- Leading provider of secured loans to venture capital-backed and private equity-backed growth stage companies
- Generate attractive risk-adjusted returns through directly originated senior secured loans and additional capital appreciation through warrants
- Focus on technology, life science, and healthcare technology

SOLID FINANCIALS

- 15% TTM average debt portfolio yield
- Strong and stable credit; no investments on non-accrual
- Expanding investment portfolio
- \$1.20 per share annual dividend
- Leveraged at 1x debt to equity

AMPLE GROWTH OPPORTUNITIES

- Robust investment pipeline in dynamic markets
- \$147M available investment capacity at HRZN and JV
- Large addressable market
- Proposed AFFE exemption would lay groundwork to allow BDCs to rejoin indexes



Deeply Experienced and Cycle-Tested Management



Robert D. Pomeroy, Jr. CEO & Chairman

- 35+ years lending experience, including 20+ years in venture lending
- Co-founder of Horizon



GATX





Gerald A. Michaud President & Director


- 35+ years lending experience including 20+ years in venture lending
- Co-founder of Horizon



GATX

FS Financing for Science International

Venture Leasing and Capital



John C. Bombara General Counsel, Secretary & Chief Compliance Officer

- 25+ years of legal experience, including 18 years in venture lending
- Founding member of Horizon



PEPE%HAZARDup



Daniel S. Devorsetz SVP, Chief Investment Officer, CFA

- 20+ years of credit and portfolio management experience, including 20 years in venture lending
- With Horizon since 2004


GATX



citigroup



IRONWOOD C A P I T A L



Daniel R. Trolio SVP & Chief Financial Officer, CPA

- 20+ years of finance and accounting experience, including 13 years in venture lending
- With Horizon since 2006



ARTHUR ANDERSEN



By The Numbers

Annualized Debt Portfolio Yield

as of Dec. 31, 2018

15.3%

Portfolio Size

as of Dec. 31, 2018

\$248.4M

Dividend Yield

as of Dec. 31, 2018

10.7%

Net Asset Value

as of Dec. 31, 2018

\$11.64

2-Year Total Return

as of Dec. 31, 2018

33.4%

Cumulative Distributions

per share since IPO

\$11.72





Sound Investments With Strong Yields



Senior secured strategy

Secured by first lien or behind bank revolver



Premium yield with capital appreciation opportunity

Multiple ways to generate yield – interest, fee prepayments, warrants



Diversified Portfolio

Diversification = lower concentration of risk



Advantageous, rapid amortization schedule

Expect prepayment of debt; can quickly redeploy capital



Significantly lower LTV than typical mid-market loan

20% LTV for HRZN loan vs. 80% LTV for mid-market loan



Equity sponsors and IPO proceeds protect HRZN investment


Have priority in terms of repayment





Large Addressable Market for Growth Capital

Ample Opportunity to Invest in Development Stage Companies



Addressable Market

\$12 Billion*

Source: PitchBook Venture Monitor 4Q 2018

Significant opportunities to deploy capital across industries

^{*} Venture debt represents 10-20% of the total venture capital invested.



Venture Loan Process – From Origination to Exit



Direct Origination

Underwriting and Due Diligence

Loan Closing and Funding

Portfolio Management and Exit

Detailed prescreen

Review business plan; model cash needs

Senior management review

Query investors

Create term sheet; negotiate

Receive award and good-faith deposit

Comprehensive site visits, discussions/assessments with all parties and management

Independent verification

Prepare model, stress projections

Create investment memorandum and present to Investment Committee

Approval

Document loan with experienced in-house counsel

Compliance with all terms of approval

Funding must be authorized by: CEO or President, CFO, Chief Compliance Officer and Chief Investment Officer

Warrants received

Hands-on approach to portfolio management

Monthly reporting by portfolio companies; quarterly reviews with management and investors

Monthly credit ratings and weekly watch list monitoring

Senior management involved in all accounts

Realize gains upon exit through M&A or IPO

Loan structuring expertise allows HRZN to obtain premium yield and collect enhanced return in event of prepayment



Predictive Pricing Strategy

Sample Portfolio Investment

Loan Interest Rate Coupon **Commitment Fees**

End of Term Payment

Prepayment Fees

Acceleration of Fees

Warrants and Equity Rights

Gross IRR

9% - 11%

10% - 13%

12% - 16%

13% - 18%

Structure integral to all HRZN loans



Dedicated Portfolio Management



1 Proactively manage each portfolio investment

Diligent, hands-on management from funding to exit – regular reviews and reporting

3 Experienced senior management involved in every investment

Comprehensive work to maintain loans in good standing with a focus on recovery of principal



Select Portfolio Companies

Current Portfolio Companies







SaaS rewards platform



Oncology drug development



Cryotherapy technology

Former Portfolio Companies



Antiviral drugs

sciences provider



Biopharma



Rare disease biopharma



Regenerative medicine



3-D fracture management



Online food community



Location data technology



Healthcare administration software



All-flash enterprise





technology



Central nervous system diseases



Neuromodulators



Customer intelligence platform



Communications platform as a service



technology



Wi-Fi network design



IT solutions for healthcare



Real-time imaging platform



iPad point-of-sale system



Silicon photonics technology



Early detection of



E-commerce platform

Therapeutics drug

delivery platform

NEWSIGNATURE

Technology consulting



Full spectrum color LED light



Tissue sealing devices



Digital dental impression system



Migraine treatment



Peptide therapeutics



Online legal

services

BIOTECH

Inhaled nitric oxide delivery system



Surgical devices



Cancer drugs





Diabetes and inflammatory diseases drugs



ACUITY





Proactive Management Drives Stable Credit

As of December 31, 2018

No loans on non-accrual

Over 90% of portfolio performing at or better than expectations

No 1-rated (lowest) loans

Weighted average credit rating of 3.1 (out of 4)

Deeply involved with 2-rated investments to ensure value-added outcome





Producing Strong Total Return

Outperforming Wells Fargo BDC index over past 24 months*

Total Return




^{*} Period from 12/31/2016 to 12/31/2018



Strong Account Management and Credit Performance Contributing to Valuation


0.97x P/NAV is Above Peer Group



Note: Peer group consists of FDUS, TCRD, MCC, HTGC, TPVG, SCM, GARS, CPTA, CMFN, ABDC, GECC



Well-Diversified Portfolio





Significant Liquidity Capacity

(\$ in millions)	Size of Commitment	Balance as of 12/31/2018	Available Capacity
Cash and Cash Equivalents	-	\$12.6	\$12.6
2022 6.25% Notes	\$37.4	\$37.4	-
KeyBank Facility (LIBOR + 3.25%)	\$125.0	\$90.5	\$34.5
Joint Venture	\$100.0	\$0.0	\$100.0
Available Capacity			\$147.1



Long-Term Growth Catalysts





HorizonTechnologyFinance

A LIFE SCIENCES & TECHNOLOGY VENTURE LENDING PARTNER

Investment Highlights

